focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Regulatory News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

20 Jan 2020 14:15



Holding(s) in Company

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Summit Therapeutics PLCSedol BN40HZ0
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rights 
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
Name 
City and country of registered office (if applicable) 
4. Full name of shareholder(s) (if different from 3.)v
NameRobert W. Duggan
City and country of registered office (if applicable) 
5. Date on which the threshold was crossed or reachedvi:14/01/2020
6. Date on which issuer notified (DD/MM/YYYY):17/01//2020
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached39.55%23.31%62.86%335,873,208
Position of previous notification (if applicable)49.47%23.31%72.78% 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of sharesISIN code (if possible)Number of voting rightsix% of voting rights
Direct(Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)Direct(Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BN40HZ01132,835,180 39.55% 
SUBTOTAL 8. A132,835,18039.55%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration datexExercise/ Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights
American Depositary Shares (ADS)n/an/a78,288,20523.31%
  SUBTOTAL 8. B 178,288,20523.31%
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration datexExercise/ Conversion Period xiPhysical or cash settlementxiiNumber of voting rights % of voting rights
      
   SUBTOTAL 8.B.2  

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiiiX
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) 
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
    
    
    
    
    
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional informationxvi
 

Place of completionFlorida, United States of America
Date of completion16/01/2020


Date   Source Headline
12th Jul 20067:00 amRNSDirector Appointment
22nd Jun 20067:00 amRNSOrphan Drug Designation
8th Jun 200611:13 amRNSResult of AGM
31st May 20069:30 amRNSEU Research Network
18th May 20068:30 amRNSVASTox Appointment
9th May 20067:02 amRNSAppointment of CFO
9th May 20067:00 amRNSFinal Results
26th Apr 20067:01 amRNSAppointment of CSO
11th Apr 20067:00 amRNSNew Drug Discovery Programme
27th Mar 200612:20 pmRNSHolding(s) in Company
23rd Mar 20061:26 pmRNSHolding(s) in Company
22nd Mar 200610:01 amRNSResult of EGM
27th Feb 20068:03 amRNSPlacing
24th Jan 20067:00 amRNSPreclinical Results in DMD
22nd Nov 20057:01 amRNS4th Discovery Programme
12th Oct 20057:00 amRNSInterim Results
7th Oct 200510:00 amRNSNew Board Appointment
2nd Aug 20057:00 amRNSChange of Adviser
21st Jul 20057:00 amRNSNew Programme
4th Jul 200510:14 amRNSHolding(s) in Company
30th Jun 20054:09 pmRNSHolding(s) in Company
20th Jun 20057:00 amRNSTwo New Agreements
3rd Jun 200512:40 pmRNSResult of AGM
3rd May 20057:00 amRNSPreliminary Results Amendment
25th Apr 20057:00 amRNSPreliminary Results
8th Apr 20057:00 amRNSDuchenne Programme Progress
10th Mar 20057:00 amRNSAppointments to SAB
23rd Feb 20057:00 amRNSContract Win
31st Jan 20057:00 amRNSDeal with MNLpharma

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.